Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).

Clark MP, George KM, Bookland RG, Chen J, Laughlin SK, Thakur KD, Lee W, Davis JR, Cabrera EJ, Brugel TA, VanRens JC, Laufersweiler MJ, Maier JA, Sabat MP, Golebiowski A, Easwaran V, Webster ME, De B, Zhang G.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1250-3. Epub 2006 Dec 9.

PMID:
17189692
2.

Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3.

Chen JJ, Thakur KD, Clark MP, Laughlin SK, George KM, Bookland RG, Davis JR, Cabrera EJ, Easwaran V, De B, George Zhang Y.

Bioorg Med Chem Lett. 2006 Nov 1;16(21):5633-8. Epub 2006 Aug 24.

PMID:
16934457
3.

The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production.

Sabat M, Vanrens JC, Clark MP, Brugel TA, Maier J, Bookland RG, Laufersweiler MJ, Laughlin SK, Golebiowski A, De B, Hsieh LC, Walter RL, Mekel MJ, Janusz MJ.

Bioorg Med Chem Lett. 2006 Aug 15;16(16):4360-5. Epub 2006 Jun 5.

PMID:
16750367
4.

Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1.

Brugel TA, Maier JA, Clark MP, Sabat M, Golebiowski A, Bookland RG, Laufersweiler MJ, Laughlin SK, Vanrens JC, De B, Hsieh LC, Mekel MJ, Janusz MJ.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3510-3. Epub 2006 May 2.

PMID:
16632356
5.

Development of N-2,4-pyrimidine-N-phenyl-N'-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 2.

Maier JA, Brugel TA, Clark MP, Sabat M, Golebiowski A, Bookland RG, Laufersweiler MJ, Laughlin SK, Vanrens JC, De B, Hsieh LC, Brown KK, Juergens K, Walter RL, Janusz MJ.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3514-8. Epub 2006 Apr 24.

PMID:
16632350
6.

The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.

Laughlin SK, Clark MP, Djung JF, Golebiowski A, Brugel TA, Sabat M, Bookland RG, Laufersweiler MJ, VanRens JC, Townes JA, De B, Hsieh LC, Xu SC, Walter RL, Mekel MJ, Janusz MJ.

Bioorg Med Chem Lett. 2005 May 2;15(9):2399-403.

PMID:
15837333
7.

The development of monocyclic pyrazolone based cytokine synthesis inhibitors.

Golebiowski A, Townes JA, Laufersweiler MJ, Brugel TA, Clark MP, Clark CM, Djung JF, Laughlin SK, Sabat MP, Bookland RG, VanRens JC, De B, Hsieh LC, Janusz MJ, Walter RL, Webster ME, Mekel MJ.

Bioorg Med Chem Lett. 2005 May 2;15(9):2285-9.

PMID:
15837310
8.

The development of new bicyclic pyrazole-based cytokine synthesis inhibitors.

Townes JA, Golebiowski A, Clark MP, Laufersweiler MJ, Brugel TA, Sabat M, Bookland RG, Laughlin SK, VanRens JC, De B, Hsieh LC, Xu SC, Janusz MJ, Walter RL.

Bioorg Med Chem Lett. 2004 Oct 4;14(19):4945-8.

PMID:
15341957
9.

The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones.

Laufersweiler MJ, Brugel TA, Clark MP, Golebiowski A, Bookland RG, Laughlin SK, Sabat MP, Townes JA, VanRens JC, De B, Hsieh LC, Heitmeyer SA, Juergens K, Brown KK, Mekel MJ, Walter RL, Janusz MJ.

Bioorg Med Chem Lett. 2004 Aug 16;14(16):4267-72.

PMID:
15261284
10.

Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production.

Clark MP, Laughlin SK, Laufersweiler MJ, Bookland RG, Brugel TA, Golebiowski A, Sabat MP, Townes JA, VanRens JC, Djung JF, Natchus MG, De B, Hsieh LC, Xu SC, Walter RL, Mekel MJ, Heitmeyer SA, Brown KK, Juergens K, Taiwo YO, Janusz MJ.

J Med Chem. 2004 May 20;47(11):2724-7.

PMID:
15139749
11.

The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.

Tullis JS, Laufersweiler MJ, VanRens JC, Natchus MG, Bookland RG, Almstead NG, Pikul S, De B, Hsieh LC, Janusz MJ, Branch TM, Peng SX, Jin YY, Hudlicky T, Oppong K.

Bioorg Med Chem Lett. 2001 Aug 6;11(15):1975-9.

PMID:
11454461
12.

Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.

Natchus MG, Bookland RG, Laufersweiler MJ, Pikul S, Almstead NG, De B, Janusz MJ, Hsieh LC, Gu F, Pokross ME, Patel VS, Garver SM, Peng SX, Branch TM, King SL, Baker TR, Foltz DJ, Mieling GE.

J Med Chem. 2001 Mar 29;44(7):1060-71.

PMID:
11297453
13.

Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.

Natchus MG, Bookland RG, De B, Almstead NG, Pikul S, Janusz MJ, Heitmeyer SA, Hookfin EB, Hsieh LC, Dowty ME, Dietsch CR, Patel VS, Garver SM, Gu F, Pokross ME, Mieling GE, Baker TR, Foltz DJ, Peng SX, Bornes DM, Strojnowski MJ, Taiwo YO.

J Med Chem. 2000 Dec 28;43(26):4948-63.

PMID:
11150165
14.

Pseudomonas cepacia suppression of sunflower wilt fungus and role of antifungal compounds in controlling the disease.

McLoughlin TJ, Quinn JP, Bettermann A, Bookland R.

Appl Environ Microbiol. 1992 May;58(5):1760-3.

15.

Induction of Bradyrhizobium japonicum common nod genes by isoflavones isolated from Glycine max.

Kosslak RM, Bookland R, Barkei J, Paaren HE, Appelbaum ER.

Proc Natl Acad Sci U S A. 1987 Nov;84(21):7428-32.

16.

Synthesis and protein body deposition of maize 15-kd zein in transgenic tobacco seeds.

Hoffman LM, Donaldson DD, Bookland R, Rashka K, Herman EM.

EMBO J. 1987 Nov;6(11):3213-21.

17.

Molecular cloning and characterization of the insecticidal crystal protein gene of Bacillus thuringiensis var. tenebrionis.

Sekar V, Thompson DV, Maroney MJ, Bookland RG, Adang MJ.

Proc Natl Acad Sci U S A. 1987 Oct;84(20):7036-40.

Supplemental Content

Loading ...
Support Center